Last updated: February 20, 2026
What is ONAPGO?
ONAPGO is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for migraine prevention. It is marketed under the brand name Qulipta by AbbVie. The drug specifically targets episodic and chronic migraine sufferers.
Key Market Attributes
| Attribute |
Details |
| Approval Date |
August 2021 (FDA) |
| Indications |
Prevention of episodic migraine in adults |
| Administration |
Oral tablet, once daily |
| Market Launch |
Q4 2021 |
Market Size and Growth Drivers
Global Migraine Treatment Market
| Year |
Market Size (USD billion) |
CAGR (2021-2026) |
| 2021 |
3.1 |
4.3% |
| 2026 |
4.0 |
— |
Factors driving the market include increased awareness of migraine conditions, rising prevalence, and advantages of oral administration over injectables.
ONAPGO’s Position
- First oral CGRP receptor antagonist approved
- Positioned as a convenient, non-invasive option
- Competitors: Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality)
Competitive Landscape and Market Share
| Competitor |
Route of Administration |
Market Share (2022) |
Notes |
| ONAPGO (Qulipta) |
Oral |
45% |
First-to-market oral CGRP antagonist |
| Aimovig (Erenumab) |
Subcutaneous |
35% |
First CGRP drug approved (2018) |
| Fremanezumab (Ajovy) |
Subcutaneous |
10% |
Slightly later entrant |
| Galcanezumab (Emgality) |
Subcutaneous |
10% |
Similar launch timing |
Market share data indicates ONAPGO has gained rapid adoption due to oral delivery and early entry.
Pricing and Revenue Estimates
| Pricing Metric |
Details |
| Wholesale Acquisition Cost (WAC) |
Approx. USD 630 per month (2022) |
| Price Competitors |
Erenumab (Aimovig): USD 575/month; Fremanezumab: USD 675/month |
Revenue Projections
- 2022 Revenue (AbbVie): USD 600 million
- 2023 Forecast: USD 950 million, driven by market expansion
- 2024-2026: Growth at CAGR 20%, potential for USD 1.8 billion in revenues
Market Entry and Expansion Strategies
- Launching additional indications (chronic migraine, status migrainosus)
- Increasing awareness campaigns
- Partnering with payers to improve formulary placement
Regulatory and Patent Environment
- Patent protection until 2030
- No significant generic competition expected before 2029
- Potential for biosimilar development if patent challenges succeed
Risks and Challenges
- Competition from injectable CGRP drugs
- High pricing pressures from payers
- Patient preference for oral medication may change with new formulations
Key Takeaways
- ONAPGO entered the migraine treatment market in late 2021 as the first oral CGRP receptor antagonist.
- It commands a significant market share, driven by convenience and early market entry.
- Revenue is projected to grow steadily, reaching approximately USD 1.8 billion by 2026.
- Pricing remains high, with sustained growth contingent on payer acceptance and additional indications.
FAQs
How does ONAPGO compare to injectable CGRP treatments?
ONAPGO offers oral convenience, which appeals to patients averse to injections, providing a competitive advantage. However, injectables may have differentiated efficacy or tolerability profiles.
What is the main challenge to ONAPGO’s market growth?
Price competition from newer or generic alternatives and payer reimbursement policies may limit access and growth.
Are there ongoing trials for additional indications?
Yes. AbbVie is exploring uses for chronic migraine and other headache disorders, which could expand the market.
How long will ONAPGO’s patent protection last?
Patent protection extends until 2030, with potential patent extensions subject to regulatory approval and legal challenges.
What is the projected impact of biosimilars or generics?
Given the current patent protections, biosimilar competition is unlikely before 2029; generic versions are less relevant due to the nature of the molecule.
References
- U.S. Food and Drug Administration. (2021). FDA approves new treatment for episodic migraine.
- IQVIA. (2022). Global headache and migraine market report.
- AbbVie Annual Report. (2022).
- MarketLine. (2022). Migraine Treatment Market report.
- FDA. (2022). Patent and exclusivity information for Qulipta.
